The California-based nonprofit founded by the former 23andMe CEO is set to close the $305 million deal in coming weeks.

The debate continues over the potential of measurable residual disease to transform research and clinical care in hematology.

Anne Wojcicki is set to regain control of 23andMe after a $305 million bid from a nonprofit she controls topped Regeneron ...

Regeneron is backing away from buying the DNA-testing company after a nonprofit controlled by co-founder Wojcicki made a ...

Regeneron founder, chairman and CEO Dr. Leonard Schleifer joins 'Squawk Box' to discuss the company's bid for 23andMe, ...

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the 11 most profitable NASDAQ stocks to buy now. On June 9, Regeneron ...

The genetic-testing company, which collected DNA data from users, is for sale in bankruptcy court. Now, 27 states and the ...

More than two dozen states, along with the District of Columbia, are suing biotechnology company 23andMe over plans to ...

UnitedHealth Group ( UNH -1.61%) was the worst-performing stock in the S&P 500 last month. It plunged 26.6% to 52-week lows of $248.88 per share on May 15 after CEO Andrew Witty abruptly resigned and ...

Anne Wojcicki won a bid to purchase the genetic testing platform through her nonprofit TTAM Research Institute. The $305M deal was part of a bankruptcy auction, beating out offers from Regeneron ...

Regeneron signed a deal with China-based Hansoh Pharma for HS-20094, an investigational, late-stage anti-obesity asset. Per ...

During a live event, Ahmad Tarhini, MD, PhD, and participants discussed how to use combination immunotherapy in patients with ...